{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:53:29Z","timestamp":1781794409346,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100015512","name":"Wockhardt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015512","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijmmb.2026.101112","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:44:28Z","timestamp":1775493868000},"page":"101112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In-vitro efficacy of levonadifloxacin against methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7500-8269","authenticated-orcid":false,"given":"Sukriti","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imola","family":"Jamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8633-3348","authenticated-orcid":false,"given":"Shubhangi","family":"Kansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Angrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-6138","authenticated-orcid":false,"given":"Neelam","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijmmb.2026.101112_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijmmb.2026.101112_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/ijmm.IJMM_16_427","article-title":"Prevalence and genetic mechanisms of antimicrobial resistance in staphylococcus species: a multicentre report of the Indian council of medical research antimicrobial resistance surveillance network","volume":"35","author":"Rajkumar","year":"2017","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.ijmmb.2026.101112_bib3","article-title":"A systemic literature review and meta-analysis reporting the prevalence and impact of methicillin-resistant Staphylococcus aureus infection in India","volume":"13","author":"Ghia","year":"2020","journal-title":"Infect Dis Res Treat"},{"key":"10.1016\/j.ijmmb.2026.101112_bib4","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijmmb.2026.101112_bib5","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s40262-017-0548-y","article-title":"Penetration of vancomycin into the cerebrospinal fluid: a systematic review","volume":"56","author":"Beach","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijmmb.2026.101112_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3947\/ic.2016.48.4.267","article-title":"Treatment of methicillin- resistant Staphylococcus aureus bacteremia","volume":"48","author":"Choo","year":"2016","journal-title":"Infect Chemother"},{"key":"10.1016\/j.ijmmb.2026.101112_bib7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10156-006-0446-Y","article-title":"Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level","volume":"12","author":"Sato","year":"2006","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijmmb.2026.101112_bib8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jac\/dkz493","article-title":"In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016\u201318","volume":"75","author":"Appalaraju","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2026.101112_bib9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1099\/jmm.0.000999","article-title":"In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin-and quinolone-resistant Staphylococcus aureus biofilms","volume":"68","author":"Tellis","year":"2019","journal-title":"J Med Microbiol"},{"issue":"363\u2013369","key":"10.1016\/j.ijmmb.2026.101112_bib10","article-title":"Methicillin resistant staphylococcus aureus (MRSA) in India: prevalence & susceptibility pattern","volume":"137","author":"Joshi","year":"2013","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijmmb.2026.101112_bib11","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2023"},{"key":"10.1016\/j.ijmmb.2026.101112_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijmmb.2022.11.005","article-title":"India-discovered levonadifloxacin & alalevonadifloxacin: a review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care","volume":"41","author":"Veeraraghavan","year":"2023","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.ijmmb.2026.101112_bib13","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence","volume":"24","author":"Bhagwat","year":"2019","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.ijmmb.2026.101112_bib14","first-page":"2156","article-title":"Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital","volume":"75","author":"Bakthavatchalam","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2026.101112_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmmb.2025.100788","article-title":"In vitro efficacy of levonadifloxacin against methicillin-resistant Staphylococcus aureus (MRSA) including hVISA isolates collected across India","author":"Vinayan","year":"2025","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.ijmmb.2026.101112_bib16","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1128\/AAC.48.9.3338-3342.2004","article-title":"In vitro activity of the new quinolone WCK 771 against staphylococci","volume":"48","author":"Jacobs","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2026.101112_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/mdr.2022.0313","article-title":"In vitro assessment of antimicrobial activity of novel fluoroquinolone, Levonadifloxacin (WCK 771) against multi-drug-resistant clinical isolates from cancer patients in India","volume":"30","author":"Bajpai","year":"2024","journal-title":"Microb Drug"},{"key":"10.1016\/j.ijmmb.2026.101112_bib18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.4103\/ijmm.IJMM_20_34","article-title":"A comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant Staphylococcus aureus agent levonadifloxacin: therapeutic role in nosocomial and community infections","volume":"37","author":"Bakthavatchalam","year":"2019","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.ijmmb.2026.101112_bib19","first-page":"10","article-title":"Intrapulmonary pharmacokinetics of levonadifloxacin following oral administration of alalevonadifloxacin to healthy adult subjects","volume":"62","author":"Rodvold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.ijmmb.2026.101112_bib20","article-title":"Evaluation of In-Vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus clinical isolates","volume":"15","author":"Roy","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ijmmb.2026.101112_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/ijabmr.ijabmr_602_21","article-title":"Prescription-event monitoring study on safety and efficacy of levonadifloxacin (oral and IV) in management of bacterial infections: findings of real-world observational study","volume":"12","author":"Mehta","year":"2022","journal-title":"Int J Appl Basic Med Res"},{"issue":"4","key":"10.1016\/j.ijmmb.2026.101112_bib22","article-title":"Real-world evidence of efficacy and safety of levonadifloxacin (oral and IV) in the management of acute bacterial skin and skin structure infections (ABSSSI): findings of a retrospective, multi-center study","volume":"14","author":"Mehta","year":"2022","journal-title":"Cureus"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085726000708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085726000708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:16:56Z","timestamp":1781792216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085726000708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"alternative-id":["S0255085726000708"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2026.101112","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vitro efficacy of levonadifloxacin against methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2026.101112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101112"}}